Experimental Ebola vaccines elicit year-long immune response
Clinical trial results show that two candidate Ebola vaccines can elicit immune responses after initial vaccination that last for at least one year...
List view / Grid view
Clinical trial results show that two candidate Ebola vaccines can elicit immune responses after initial vaccination that last for at least one year...
The regulatory environment has a great impact on business, especially in healthcare. Non-compliance exposes companies to the risk of launch delay, delisting products from the market and out-of-stocks. Moreover, it can cause reputational damage affecting staff, consumer and shareholder confidence, reduce market opportunities, and affect the bottom line.
This article reviews the trends in freeze drying highlighted at recent Parenteral Drug Association (PDA) conferences...
An industry work-group comprising of toxicologists, pharmaceutical companies and data experts plans to unveil the early results of a data sharing project...
6 June 2017 | By Niamh Marriott, Junior Editor
Regulatory submissions to the EMA and FDA for a single-tablet, two-drug regimen of dolutegravir & rilpivirine for the maintenance treatment of HIV...
16 May 2017 | By European Federation of Pharmaceutical Industries and Associations (EFPIA)
The EMA is a world class regulator, whose scientific recommendations are a vital element of the ongoing effort to provide EU citizens with quality medicines
31 March 2017 | By Niamh Marriott, Junior Editor
Emma Walmsley will succeed Andrew Witty as GSK CEO, when he retires on 31 March 2017, making her the first female CEO of a major global pharmaceuticals company.
European Pharmaceutical Review has been keeping the industry informed for 21 years and continues to bring insights into current and emerging technologies, contributions from recognised figures in the life science community and of course, the latest and most up to date news. To celebrate our success, we will be counting down…
5 December 2016 | By Niamh Louise Marriott, Digital Editor
Mepolizumab is the first biologic treatment to target specific white blood cells called eosinophils, which are responsible for symptoms of severe asthma...
23 November 2016 | By Niamh Louise Marriott, Digital Content Producer
The two studies, FLAIR and ATLAS, will examine the safety and efficacy of monthly dosing with the two-drug, injectable regimen in both treatment-naïve...
14 November 2016 | By Niamh Louise Marriott, Digital Content Producer
Read how the 2016 Access to Medicine Index ranks the top 20 pharmaceutical companies on their efforts to improve access to medicine in low- and middle-income countries...
20 September 2016 | By Niamh Louise Marriott, Digital Content Producer
She will succeed Andrew Witty as GSK CEO, when he retires on 31st March 2017. She will be the first female CEO of a major global pharmaceuticals company...
16 September 2016 | By Niamh Louise Marriott, Digital Content Producer
Sirukumab is a human monoclonal IgG1 kappa antibody that targets the cytokine IL-6, a protein believed to play a role in autoimmune rheumatoid arthritis...
16 August 2016 | By ViiV Healthcare
ViiV Healthcare is undertaking two identical studies as part of a global phase III programme comparing a two-drug regimen of dolutegravir plus lamivudine, with a three-drug regimen of dolutegravir (Tivicay), plus the fixed-dose tablet tenofovir/emtricitabine (Truvada), to support regulatory filings as a treatment for HIV, for adults who have had…
21 July 2016 | By Niamh Louise Marriott, Digital Content Producer
global pharmaceutical company GlaxoSmithKline has been established to discover and develop novel medicines to treat aggressive forms of blood cancer...